Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Drew M. Pardoll(Bloomberg (United States)), Victor E. Velculescu(Johns Hopkins University), Gary L. Rosner(Johns Hopkins University), Julie R. Brahmer(Johns Hopkins University), Stephen C. Yang(Johns Hopkins University), Stephen Broderick(Johns Hopkins University), Matthew D. Hellmann(AstraZeneca (United States)), Janis M. Taube(Bloomberg (United States)), John-William Sidhom(Cornell University), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), James R. White(Resphera Biosciences), Suzanne L. Topalian(Bloomberg (United States)), Jedd D. Wolchok(Cornell University), Valerie W. Rusch(Memorial Sloan Kettering Cancer Center), Valsamo Anagnostou(Johns Hopkins University), Kristen A. Marrone(Johns Hopkins University), Marianna Zahurak(Bloomberg (United States)), David R. Jones(Memorial Sloan Kettering Cancer Center), Robert B. Scharpf(Johns Hopkins University), Tricia R. Cottrell(Queen's University), Natasha Rekhtman(Memorial Sloan Kettering Cancer Center), Kellie N. Smith(Bloomberg (United States)), Justina X. Caushi(Aeras), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), Jiajia Zhang(Bloomberg (United States)), Hao Wang(The University of Sydney), Moises J. Velez(Memorial Sloan Kettering Cancer Center), Zachary T. Olah(Memorial Sloan Kettering Cancer Center), Haidan Guo(Bloomberg (United States)), Edward Gabrielson(Bloomberg (United States)), Hok Yee Chan(Johns Hopkins University), Franco Verde(Bloomberg (United States)), Richard J. Battafarano(Johns Hopkins University), Taha Merghoub(Cornell University)
New England Journal of Medicine
April 16, 2018
Cited by 2,131


Related Papers